TG Therapeutics, Inc. Stock News

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, bei...

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, March 3, 2025, at 8:30 AM ET to discuss results for the fourth quarter and full year 2024 and to provide a business outlook for 2025. Michael S.

The co-chief investment officers at Neuberger Berman see a new dynamic in the stock market as investors move on from inflation worries.

TG Therapeutics CEO Michael Weiss says his biotech company is small, but "mighty." But TG stock's move has been anything but small.

TG Therapeutics presented at the JP Morgan Healthcare conference this month and CEO Weiss provided commercial and pipeline updates. Briumvi's strong Q4 2024 performance, with $103.6 million in net sales, and 2025 outlook highlight its growth potential despite recent new competition from Roche's Ocrevus Zunovo. Pipeline updates include subcutaneous Briumvi entering phase 3 trials in mid-2025 and...

TG Therapeutics exceeded 2024 revenue guidance by 24%, signaling strong growth and market share capture with its Multiple Sclerosis treatment, Briumvi. 2025 revenue guidance of $540 million implies slower growth, but management and data suggest potential for significantly higher revenue, possibly reaching $605 million. CEO comments and Q4 performance indicate sustained 15-20% new patient growth...

TG Therapeutics is already marketing an IV infusion of Briumvi, but is also developing a subcutaneous form, which could help it compete with other multiple sclerosis drugs. The company expects to report initial data on the subcutaneous form of Briumvi in early 2025, which could be positive given the company's upbeat statements on its prospects. While the company has approved a $100M share buyba...

NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will present at the 43rd Annual J.P.